Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly

Vaccine

Volumn 30, Issue 7, 2012, Pages 1388-1396

  Vesikari, Timo ^a   Forstén, Aino ^a   Herbinger, Karl Heinz ^b   Cioppa, Giovanni Della ^c   Beygo, Jenny ^c   Borkowski, Astrid ^c   Groth, Nicola ^c   Bennati, Mariaviviana ^c   Von Sonnenburg, Frank ^b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c GSK Marburg Vaccines and Diagnostics   (Germany)

Author keywords

Avian influenza; H5N1; Heterologous immunity; MF59; Pandemic

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; PLACEBO;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG SAFETY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HEMOLYSIS; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; IMMUNOGENICITY; INFLUENZA VACCINATION; LICENSING; MALE; MICRONEUTRALIZATION ASSAY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE RADIAL HEMOLYSIS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CROSS PROTECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; VACCINATION; YOUNG ADULT;

EID: 84856564196     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.009     Document Type: Article

References (36)

1. Poland G.A. Vaccines against avian influenza-a race against time. N Engl J Med 2006, 354(13):1411-1413.
2. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005, 352(4):333-340.
3. Shortridge K.F. Influenza pandemic preparedness: gauging from EU plans. Lancet 2006, 367(9520):1374-1375.
4. Mounier-Jack S., Coker R.J. How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet 2006, 367(9520):1405-1411.
5. Chen H., Smith G.J., Li K.S., Wang J., Fan X.H., Rayner J.M., et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A 2006, 103(8):2845-2850.
6. Stephenson I., Gust I., Kieny M.P., Pervikov Y. Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis 2006, 6(2):71-72.
7. Sambhara S., Poland G.A. Avian influenza vaccines: what's all the flap?. Lancet 2006, 367(9523):1636-1638.
8. World Health Organization. Confirmed human cases of avian influenza A (H5N1). http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_08_31/en/index.html.
9. Stohr K. Vaccinate before the next pandemic?. Nature 2010, 465(7295):161.
10. Webster R.G., Govorkova E.A. H5N1 influenza-continuing evolution and spread. N Engl J Med 2006, 355(21):2174-2177.
11. Wood J.M. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 2002, 20(Suppl. 5):B40-B44.
12. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(13):1343-1351.
13. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357(9272):1937-1943.
14. Podda A., Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003, 2(2):197-203.
15. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009, 4(2):e4384.
16. Galli G., Hancock K., Hoschler K., DeVos J., Praus M., Bardelli M., et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 2009, 106(19):7962-7967.
17. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005, 191(8):1210-1215.
18. Stephenson I., Nicholson K.G., Hoschler K., Zambon M.C., Hancock K., DeVos J., et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008, 359(15):1631-1633.
19. Pellegrini M., Nicolay U., Lindert K., Groth N., Cioppa G.D. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009, 27(49):6959-6965.
20. Palese P. Influenza: old and new threats. Nat Med 2004, 10(12 Suppl.):S82-S87.
21. Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008, 26(12):1525-1529.
22. Del Giudice G., Hilbert A.K., Bugarini R., Minutello A., Popova O., Toneatto D., et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006, 24(16):3063-3065.
23. Gasparini R., Pozzi T., Montomoli E., Fragapane E., Senatore F., Minutello M., et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001, 17(2):135-140.
24. Minutello M., Senatore F., Cecchinelli G., Bianchi M., Andreani T., Podda A., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999, 17(2):99-104.
25. Banzhoff A., Nacci P., Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003, 49(3):177-184.
26. De Roux A., Marx A., Burkhardt O., Schweiger B., Borkowski A., Banzhoff A., et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine 2006, 24(10):1537-1542.
27. Iorio A.M., Francisci D., Camilloni B., Stagni G., De Martino M., Toneatto D., et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003, 21(25-26):3629-3637.
28. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003, 21(15):1687-1693.
29. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006, 43(9):1135-1142.
30. Stephenson I., Nicholson K.G., Wood J.M., Zambon M.C., Katz J.M. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004, 4(8):499-509.
31. Schild G.C., Pereira M.S., Chakraverty P. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 1975, 52(1):43-50.
32. Tsai T.F., Crucitti A., Nacci P., Nicolay U., Cioppa G.D., Ferguson J., et al. Explorations of clinical trials and pharmacovigilance databases of MF59((R))-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011, 43:702-706.
33. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18(13):1217-1225.
34. Vesikari T., Karvonen A., Tilman S., Borkowski A., Montomoli E., Banzhoff A., et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010, 126:e762-e770.
35. Gioia C., Castilletti C., Tempestilli M., Piacentini P., Bordi L., Chiappini R., et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008, 14(1):121-128.
36. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27(45):6291-6295.